Aug 2026· BioNanoScience· Vol 16· 0 citations· 167 references
TL;DR
This review provides a comprehensive and critical overview of recent advances in the engineering strategies, biological membrane sources, and biomedical applications of BCNCs and critically evaluates the biological advantages, therapeutic potential, and translational limitations associated with different membrane sources and engineering approaches.
Cancer remains a major health concern worldwide, with the need to identify better and more specific treatment measures. The concept of using metallic nanoparticles in drug delivery has attracted significant attention due to their distinct physicochemical characteristics, including surface area, size, and multifunctiona...
Hiti Narula, R. Kamal, Thakur Gurjeet Singh et al.· Nanomedicine: Nanotechnology...· 1 citation
The application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, are summarized, and the major challenges in clinical translation and future perspectives for EV-based targeted therapies are discussed.
Giulia Duca, Vincenza Tinnirello, N. Ganji et al.· Molecular Biomedicine· 1 citation
This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane-integrated nanovesicles (NVs) as "living interfaces" for non-viral gene therapy.
Clara Baldari, Claudia Leone, G. Leccese et al.· Advanced Healthcare Material...· 0 citations
Biomimetic nanomedicine utilizing cell membrane cloaking has emerged as a promising approach to enhance nanocarrier performance by integrating the physicochemical benefits of synthetic nanoparticles with the biological functionalities of source cells. Nonetheless, single-source membrane systems are inherently limited b...
Yang Chen, Xu Yuan, Yilin Huang et al.· Journal of Controlled Releas...· 1 citation
A structured translational roadmap is proposed that prioritizes biologically predictive design, fit-for-purpose safety assessment, scalable good manufacturing practice production, early regulatory alignment, and clinically meaningful benefit over unnecessary structural complexity.
Yi Li, Rui Luo, Yuxuan Li et al.· Biomedicine & pharmacotherap...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.